Pfizer Inc. (PFE)
| Market Cap | 162.56B |
| Revenue (ttm) | 68.54B |
| Net Income (ttm) | 10.48B |
| Shares Out | 5.65B |
| EPS (ttm) | 1.83 |
| PE Ratio | 15.73 |
| Forward PE | 13.63 |
| Dividend | $1.68 (5.84%) |
| Ex-Dividend Date | Jan 25, 2024 |
| Volume | 30,035,470 |
| Open | 28.78 |
| Previous Close | 28.79 |
| Day's Range | 28.54 - 28.87 |
| 52-Week Range | 25.76 - 51.60 |
| Beta | 0.56 |
| Analysts | Buy |
| Price Target | 40.38 (+40.26%) |
| Earnings Date | Jan 30, 2024 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and P... [Read more]
Financial Performance
In 2022, Pfizer's revenue was $100.33 billion, an increase of 23.43% compared to the previous year's $81.29 billion. Earnings were $31.37 billion, an increase of 42.74%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PFE stock is "Buy." The 12-month stock price forecast is $40.38, which is an increase of 40.26% from the latest price.
News
Pfizer, big drugmakers expected to hike prices on at least 500 drugs in January
The expected price hikes come as the pharmaceutical industry gears up for the Biden Administration to publish significantly discounted prices for 10 high-cost drugs in September, and continues to cont...
Tax-loss selling makes these stocks in cannabis, pharma, energy and industrials worth buying
In an annual year-end ritual, investors have dumped many of their stock losers to offset taxable gains. This so-called “tax loss selling” can create buying opportunities in promising names.
Moderna and Pfizer Stock Tumbled in 2023. Wall Street Sees a Rebound.
Covid-19-vaccine makers Moderna and Pfizer saw shares drop in 2023, but analysts expect double-digit-percentage gains next year.
Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.
Things could hardly have gone worse for healthcare investors this year.
13 stocks that are down for 2023 but may bounce back in 2024 or beyond
Some investors put themselves in “value” or “growth” camps, either preferring to invest in companies trading low to book value, or expected earnings or by some other measure, or preferring to focus on...
Pfizer's chaotic year wraps up with plunging stock, grim guidance
Investors who own Pfizer Inc. NYSE: PFE may have expected 2023 to be what football teams call a "rebuilding year." The company shifted its focus away from COVID-19 drugs and toward potential deals, sh...
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, Jan...
The weight loss drug boom isn't over yet — here's what to expect in the year ahead
2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance coverage and unpleasant side effects.
The Score: Macy's, Hasbro, Pfizer and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news.
PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer
– PADCEV plus pembrolizumab approved based on groundbreaking EV-302 trial – – Confirmatory trial found PADCEV plus pembrolizumab nearly doubled median overall survival compared to standard of care pla...
We see Big Pharma going after smaller biotechs in 2024, says Jefferies' Michael Yee
Michael Yee, Jefferies senior biotech analyst, joins 'Squawk Box' to discuss the state of the biotech industry, impact of interest rate environment on the sector, growth outlook in 2024, obesity drug ...
Quick list of bargain stocks to end the year
Here's a quick economics lesson to return to the good old college days. When markets think that a country's GDP is set to grow in the future, they will turn bullish (massively bullish) toward equity m...
Pfizer Helped Save the World With Covid Vaccines. Now It Needs to Right Itself.
The drugmaker is pulling back on some of its research programs and laying off workers after overestimating pandemic-product sales.
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
Nona Biosciences will receive a total of up to $53 Million in upfront and near-term payments, with the potential for milestones of up to $1.05 billion plus royalties. Pfizer partnership expands Nona's...
Pfizer increases dividend by one penny to 42 cents a share
Pfizer Inc. PFE, -1.99% said late Thursday that its board of directors declared an increase in the company's quarterly dividend to 42 cents a share, from 41 cents a share. The dividend is payable Marc...
Pfizer Declares First-Quarter 2024 Dividend
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company's common stock to $0.42 for the first-...
Pfizer Completes Acquisition of Seagen
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops a...
How Pfizer's $43B acquisition of Seagen may impact Seattle and broader biotech market
Editor's note: William Canestaro is managing director at Seattle venture capital firm WRF Capital and leads the biotechnology investment team.
Midday Movers: Vertex Surges on Gene-Editing Deal, Pfizer Falls on Guidance Miss
U.S. equities were slightly higher at midday ahead of comments from the Federal Reserve following its last meeting of the year. It's expected the central bank won't raise interest rates any further to...
Pfizer shares sink after it resets 2024 COVID expectations
Pfizer, Inc. on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, driving shares down 9% to a 10-year low.
Pfizer Shares Dropped to Their Lowest Level in Over 10 Years—Here's Why
Pfizer (PFE) shares tumbled over 8% in early trading Wednesday to their lowest level in more than 10 years after warning revenue could decline next year and releasing guidance below forecasts as deman...
Pfizer Becomes Oversold
The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important ...
Pfizer shares fall as 2024 revenue and profit forecast disappoints
After raking in billions from Covid products, Pfizer has struggled to navigate a world beyond the pandemic and reassure investors about its growth potential.